RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for male patients, frequent death during adolescence or early adulthood. Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart.

An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. and EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months.

Frequently Asked Questions

The Natural History of a Disease is the typical progression of the disease over a person’s lifetime starting from its onset

Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time. This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or lab test results), that may contribute to better or worse disease outcomes.

Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge.

Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience.

Engaging in a Natural History Study offers numerous benefits to the community, such as:

  • Raising awareness in medical, academic and pharmaceutical sectors
  • Empowering rare disease patient communities with knowledge and support for advocating better healthcare policies and support services
  • Enhancing patient care with improved insights into disease progression, allowing for more personalized treatment plans and potentially earlier detection of complications
  • Contributing to advancements in healthcare

These studies provide various avenues to help inform and design clinical trials, such as:

  • Highlighting areas of unmet medical need
  • Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective.
  • Describing disease progression, enabling the identification of clinical outcome measures and biomarkers
  • Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments.

Interested in learning more?
Visit our Patients & Caregivers page or email us at clinicaltrials@nullrocketpharma.com

View more details about the Phase 2 pivotal trial of RP-A501 and natural history study on clinicaltrials.gov.

To read our Expanded Access statement, click here.

RARE DISEASE DAY 2024

Rocket Pharma - Rare Disease Day Logo
Rare Disease Day 2024

ROCKET PHARMA CELEBRATES RARE DISEASE DAY 2024

LEAP INTO ACTION FOR RARE

At Rocket, we are laser-focused on addressing the unmet needs of patients living with rare, life-threatening diseases. We understand living with a rare disease is much more than the disease itself. It involves fighting misconceptions, finding informed, patient and compassionate caregivers, and seeking accurate information about available treatment options.

As ardent advocates for the rare disease community, Rare Disease Day presents a timely opportunity to raise awareness and contribute to educating communities at the highest level, while aiming to ensure patients and their loved ones have access to the information and resources that they need to help connect and empower them on their journey.

In celebration of Rare Disease Day 2024, Rocket held an event at the Liberty Science Center in Jersey City, NJ. Among several topics, the event featured a tribute to Vicki Modell, cofounder of the Jeffery Modell Foundation, and inspiring advocate for patients living with primary immunodeficiency diseases, and inspirational stories from patients living with rare diseases.

Welcome & Event Overview l The Meaning of Rare Disease Day

Opening Remarks: Kinnari Patel, PharmD, MBA, President, Head of R&D and Chief Operating Officer, Rocket Pharma

Overview of Event: Latika Hickey, PharmD, Senior Director, Patient Advocacy, Rocket Pharma

Panel Discussion l Rare Disease Diagnosis Odyssey

Disease Overview: Matthew Coggins, MD, Senior Medical Director, AAV, Rocket Pharma

Panelists:
Becky, Dilated Cardiomyopathy Patient and Caregiver

Abigail Yesso, MS, Genetic Counselor, Texas Childrens

Greg Ruf, Executive Director & Board President, DCM Foundation

Moderator: Erika Zannou-Mantri, PharmD, PhD, MBA, SVP, Development Operations & Global Program Head, Rocket Pharma

Tribute l Remembering Vicki Modell

Gayatri Rao, MD, JD, Chief Regulatory Officer & SVP, Clinical Safety, Rocket Pharma

The Man with Nine Lives

Disease Overview: Eileen Nicoletti, MD, Medical Director, Fanconi Anemia/PKD, Rocket Pharma

Panelist: Altaf, Rare Amyloidosis Patient, Biotech/Biopharma Commercial Consultant and Leader

Moderator: Latika Hickey, PharmD, Senior Director, Patient Advocacy, Rocket Pharma

Mindfulness Meditation and Rare Disease: Taking Care of Your Mind

Introduction: Jonathan Schwartz, MD, Chief Medical & Gene Therapy Officer, Rocket Pharma

Speaker: David Nichtern, Emmy Award-Winning Composer & Musician and Buddhist Teacher

Forbes Spotlight l Inside Rocket Pharma’s Pursuit of Gene Therapy Cures for Rare Diseases

Panelists:
Maneet Ahuja, Editor-At-Large, Forbes

Gaurav Shah, MD, Chief Executive Officer, Rocket Pharma

Kinnari Patel, PharmD, MBA, President, Head of R&D and Chief Operating Officer, Rocket Pharma

Scroll to Top